CN117581101A - 用于免疫疗法的肿瘤生物标志 - Google Patents

用于免疫疗法的肿瘤生物标志 Download PDF

Info

Publication number
CN117581101A
CN117581101A CN202180061391.6A CN202180061391A CN117581101A CN 117581101 A CN117581101 A CN 117581101A CN 202180061391 A CN202180061391 A CN 202180061391A CN 117581101 A CN117581101 A CN 117581101A
Authority
CN
China
Prior art keywords
icos
foxp3
positive cells
positive
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180061391.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·C·A·圣松
C·迪安托尼奥
C·H·徐
L·C·陆
L·A·谢里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemab Co ltd
Original Assignee
Kemab Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemab Co ltd filed Critical Kemab Co ltd
Publication of CN117581101A publication Critical patent/CN117581101A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180061391.6A 2020-05-14 2021-05-13 用于免疫疗法的肿瘤生物标志 Pending CN117581101A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2007099.1A GB202007099D0 (en) 2020-05-14 2020-05-14 Tumour biomarkers for immunotherapy
GB2007099.1 2020-05-14
PCT/EP2021/062778 WO2021229032A1 (en) 2020-05-14 2021-05-13 Tumour biomarkers for immunotherapy

Publications (1)

Publication Number Publication Date
CN117581101A true CN117581101A (zh) 2024-02-20

Family

ID=71135069

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180061391.6A Pending CN117581101A (zh) 2020-05-14 2021-05-13 用于免疫疗法的肿瘤生物标志

Country Status (12)

Country Link
US (1) US20230176060A1 (enExample)
EP (1) EP4150347A1 (enExample)
JP (1) JP2023526044A (enExample)
KR (1) KR20230009507A (enExample)
CN (1) CN117581101A (enExample)
AU (1) AU2021271120A1 (enExample)
BR (1) BR112022022250A2 (enExample)
CA (1) CA3178642A1 (enExample)
GB (1) GB202007099D0 (enExample)
IL (1) IL298164A (enExample)
MX (1) MX2022014247A (enExample)
WO (1) WO2021229032A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1003648C2 (nl) 1996-07-19 1998-01-21 Carino Cornelis Sunderman Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP1740617B1 (en) 2004-04-23 2013-10-16 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
DE102007039429A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur Aktivierung regulatorischer T-Zellen
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
EP3147297B1 (en) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
KR20140142719A (ko) * 2012-03-30 2014-12-12 제넨테크, 인크. 암의 치료를 위한 진단 방법 및 조성물
DE102012013637A1 (de) 2012-07-09 2014-01-09 Iwis Motorsysteme Gmbh & Co. Kg Triebstockplanetengetriebe
EP2872646B1 (en) 2012-07-12 2017-08-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
EP2880180B1 (en) 2012-08-06 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and kits for screening patients with a cancer
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
EP2738557A1 (en) * 2012-12-03 2014-06-04 Université Libre de Bruxelles Organized immune response in cancer
EP3090066A4 (en) 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
JP2018503373A (ja) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
RU2769282C2 (ru) * 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11858996B2 (en) * 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
JP7235508B2 (ja) * 2016-11-24 2023-03-08 第一三共株式会社 Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法
WO2018122245A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018225063A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
CN112703012A (zh) 2018-05-14 2021-04-23 震动疗法公司 治疗癌症的方法
EP3849666B1 (en) 2018-09-14 2026-04-15 Université de Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen

Also Published As

Publication number Publication date
IL298164A (en) 2023-01-01
BR112022022250A2 (pt) 2022-12-27
GB202007099D0 (en) 2020-07-01
AU2021271120A1 (en) 2023-02-02
CA3178642A1 (en) 2021-11-18
MX2022014247A (es) 2022-12-02
EP4150347A1 (en) 2023-03-22
JP2023526044A (ja) 2023-06-20
WO2021229032A1 (en) 2021-11-18
US20230176060A1 (en) 2023-06-08
KR20230009507A (ko) 2023-01-17

Similar Documents

Publication Publication Date Title
KR102713203B1 (ko) Lag-3 양성 종양의 치료
CN111094352B (zh) B7-h4抗体及其使用方法
RU2765410C2 (ru) Способы лечения рака, включающие связывающие tigit агенты
CN117581101A (zh) 用于免疫疗法的肿瘤生物标志
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
JP6889660B2 (ja) 抗ｎｋｇ２ａ剤を用いた癌の処置
CN112516302B (zh) 抗lag-3抗体与抗pd-1抗体联合治疗肿瘤
AU2006269266B2 (en) Anti-alpha v beta 6 antibodies and uses thereof
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
CN115279786B (zh) Ssea-4结合成员
KR20220034167A (ko) Dll3-표적화 항체 및 이의 용도
KR20260046247A (ko) 흑색종을 위한 조합 요법
KR20170003937A (ko) Ceacam1에 대한 인간화 항체
KR20210040080A (ko) 암의 치료를 위한 lag-3 조합 요법
KR20220016802A (ko) 항-nme 항체 및 암 또는 암 전이의 치료 방법
KR20220093349A (ko) 흑색종에 대한 lag-3 길항제 요법
KR20230028796A (ko) 항-nme 항체 및 암 또는 암 전이의 치료 방법
KR20230021699A (ko) 항-nme 항체 및 암 또는 암 전이의 치료 방법
EP2322610B1 (en) Anti-human clcp1 antibody and use thereof
JP2020143122A (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
RU2838858C1 (ru) Опухолевые биомаркеры для иммунотерапии
US20250044295A1 (en) Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
WO2024251051A1 (en) Combination therapies involving claudin 18.2 antagonists for treatment of cancer
CN117460529A (zh) 抗icos抗体的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination